Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tolvaptan tablet

A technology for tolvaptan and tolvaptan tablets, which is applied in the field of tolvaptan tablets and a preparation thereof, can solve the problems of poor solubility of tolvaptan, failure to solve the dissolution rate of tolvaptan, and the like, and achieves dissolution The effect of stable in vitro dissolution curve and high yield

Inactive Publication Date: 2017-12-05
TIANJIN HANKANG PHARMA BIOTECH
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The existing technology adopts various methods to solve the technical obstacle of poor solubility of tolvaptan, but none of them can solve the dissolution rate of tolvaptan during 0 days or long-term storage, and fail to solve the problem of tolvaptan within the validity period. Can release more than 85% within 15 minutes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tolvaptan tablet
  • Tolvaptan tablet

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] prescription:

[0017] Tolvaptan 30g

[0018] Sorbitol 30g

[0019] Calcium hydrogen phosphate 150g

[0020] Micronized silica gel 5g

[0021] Magnesium Stearate 1g

[0022] Preparation method: heat and melt sorbitol in a hot-melt extruder, then add tolvaptan to melt, extrude the molten liquid to make granules, and directly compress it with calcium hydrogen phosphate, micro-powder silica gel, and magnesium stearate

Embodiment 2

[0024] prescription:

[0025] Tolvaptan 30g

[0026] Sorbitol 150g

[0027] Calcium hydrogen phosphate 200g

[0028] Micronized silica gel 5g

[0029] Magnesium Stearate 2g

[0030] Preparation method: heat and melt sorbitol in a hot-melt extruder, then add tolvaptan to melt, extrude the molten liquid to make granules, and directly compress it with calcium hydrogen phosphate, micro-powder silica gel, and magnesium stearate.

Embodiment 3

[0032] prescription:

[0033] Tolvaptan 30g

[0034] Sorbitol 90g

[0035] Calcium hydrogen phosphate 220g

[0036] Micronized silica gel 10g

[0037] Magnesium Stearate 2g

[0038] Preparation method: heat and melt sorbitol in a hot-melt extruder, then add tolvaptan to melt, extrude the molten liquid to make granules, and directly compress it with calcium hydrogen phosphate, micro-powder silica gel, and magnesium stearate.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Medium volumeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Wavelengthaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a kind of tolvaptan tablet, and the invention belongs to the new technical field of medicine manufacturing, specifically relates to tolvaptan tablet and a kind of preparation method thereof, and this tablet is tolvaptan as main component, is produced by tolvaptan Protan solid dispersion granules and auxiliary materials are directly compressed into tablets. The tolvaptan tablet of the invention solves the problem of in vitro dissolution of the tolvaptan, improves the curative effect of the drug, and has a more ideal therapeutic effect.

Description

technical field [0001] The invention belongs to the field of new technology for medicine manufacture, and in particular relates to a tolvaptan tablet and a preparation method thereof. Background technique [0002] Tolvaptan was developed by Japan’s Otsuka Pharmaceutical Company and was launched in the United States and Europe in 2009. Its chemical name is: N-[4-[(5R)-7-chloro-5-hydroxy-2,3,4,5- Tetrahydro-1-benzazepine-1-formyl]-3-methylphenyl]-2-methylbenzamide, mainly used in the treatment of heart failure, liver cirrhosis and antidiuretic hormone deficiency syndrome Hyponatremia in patients. [0003] Tolvaptan is a category IV drug in the BCS classification, that is, a drug with low solubility and low permeability. For poorly soluble drugs, dissolution is the rate-limiting process of absorption and is often the most important factor affecting their bioavailability. [0004] The existing technology adopts various methods to solve the technical obstacle of poor solubilit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/20A61K31/55A61K47/10A61P9/04A61P1/16A61P3/12
CPCA61K31/55A61K9/2018A61K9/2095
Inventor 严洁王志凤
Owner TIANJIN HANKANG PHARMA BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com